81 results about "Drug/agent" patented technology

A computerized electro-mechanical drug delivery device (10) configured to deliver at least one dose of two or more medicaments. The device comprises a control unit (300). An electro-mechanical drive unit (500, 600) is operably coupled to the control unit and a primary reservoir (90) for a first medicament and a secondary reservoir (100) for a fluid agent, e.g. a second medicament. An operator interface (60) is in communication with the control unit (300). A single dispense assembly (200) is configured for fluid communication with the primary (90) and the secondary (100) reservoir. Activation of the operator panel sets a first dose from the primary reservoir and based on the first dose and a therapeutic dose profile (860), the control unit (300) is configured to determine a dose or range of the fluid agent. Alternatively, the control unit determines or calculates a dose or range of a third medicament.

The invention is an apparatus and method for treatments and targeted drug delivery into a living patient, particularly but not exclusively using magnetic resonance (MR) imaging. The apparatus and method are useful in delivery to all types of living tissue and uses MR Imaging to track the location of drug delivery and estimating the rate of drug delivery. An MR-visible drug delivery device positioned at a target site (e.g., intracranial delivery) delivers a diagnostic or therapeutic drug solution into the tissue (e.g., the brain). The spinal distribution kinetics of the injected or infused drug agent are monitored quantitatively and non-invasively using water proton directional diffusion MR imaging to establish the efficacy of drug delivery at a targeted location.

Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues. This is in addition to allowing for controlled drug release. Systems and methods for large-scale electrospinning productivity are described, including novel microarchitectures allowing for variable pharmacokinetics in drug release.

The present invention provides methods and kits useful for determining rates of replication and destruction of an infectious agent within an infected host organism. In the methods of the invention, an isotopically-labeled precursor molecule is administered to an infected host, and is given sufficient time to pass into the host's metabolic pools into a biochemical component of the infectious agent. The isotopic content and/or pattern or the rate of change of the isotopic content and/or pattern of the biochemical component is then measured to determine the rate of replication (growth) of the infectious organism while in the host. Alternatively, isotopic decay of labeled molecular components of the infectious agent is measured over time after discontinuing administration of the isotopically labeled precursor molecule to determine the rate of destruction (death) of the infectious agent while in the host. Thus, using methods of the invention, in vivo sensitivity of infectious agents to drug agents may be determined, in order to optimize therapy of the infected host.

The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.

Compositions and methods for making robust pellets that contain a high percentage, by weight, of active drug agent, and which also contain additional components that enhance the absorption and solubility of the active drug agent within the gastrointestinal tract (GI tract) without diminishing the robust nature of the pellet, are disclosed.

A medical device, for example, an endoscope or catheter, includes local drug delivery capabilities for selectively delivering at least one drug in vivo. The local drug delivery may occur as the medical device is advanced through tortuous passageways of the patient's body or may occur after the medical device has reached its targeted destination. The medical device includes a drug agent, for example, carried in or on a hydrophilic or hydrogel coating disposed on the outside thereof. When the hydrogel or drug agent receives an appropriate signal, e.g., solution containing a triggering agent or triggering condition, e.g., heat or light, the hydrogel contracts or expands to squeeze out the drug from hydrogel. If electric current is provided as the signal, and the drug agent is charged, the drug agent is released by electrophoretic forces.

The invention discloses a stable nanometer gel of core-shell structure and application in the macromolecular chemistry and drug agent technical domain, which is characterized by the following: reacting protein and Maillard of polysaccharide to form protein-polysaccharide covalent compound; heating the protein-polysaccharide covalent compound solution under certain pH value; obtaining the product as micromolecular carrier; loading micromolecular drug and nourishing material in the dispersing or gel forming course; obtaining the nanometer particle of drug and nourishing material.

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.

The invention discloses a compound and medical acceptable salt with general formula (I) and making method and their drug agent, which possesses better COX-2 expressive inhibiting and TNF-alpha inhibiting and IL-6 inhibiting action.

The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptidic moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.

This invention defines novel research and clinical laboratory methodology and compositions related thereto appropriate for use in (a) determining the presence of a neurodegenerative disease selected from the group limited solely to Charcot-Marie-Tooth disease, familial Alzheimer's disease, familial Parkinson's disease, Huntington's disease, spinal muscular atrophy, Friedreich'a ataxia, giant axon neuropathy, juvenile ceroid-lipofuscinosis, familial motor neuron diseases, juvenile diabetic polyneuropathy and Down's syndrome, (b) monitoring the ongoing status of the physiological expression of said disease and (c) screening candidate therapeutic drug agents for possible effectiveness. The invention is based on the new and novel observation that the presence of a neurodegenerative disease can be characterized in part by the expression in cultured fibroblasts obtained from the patient of one or more proteins which are not the product of a defective disease-inducing gene, but which are stress proteins, one or more other proteins modified by conditions of oxidative stress or one or more other disease-related proteins. The invention depends on living cell material, namely fibroblasts, which are readily and, if necessary, repeatedly available from a patient. When adapted as a method and composition useful for the screening candidate therapeutic drug agents for possible effectiveness, this technology offers advantages in terms of (a) providing research opportunities which, in some cases, never existed before, (b) cost effectiveness when compared to alternative technologies, (c) ability to be used readily on a large scale, (d) ability to generate meaningful data in a comparatively short period of time, and (e) providing an early stage opportunity to obtain information based on direct interaction of a candidate drug and a living tissue disease model. Various aspects of diagnostic methods and compositions are also disclosed.

A medicament delivery device is shown for the administration of one or more drug agents. The device comprises a medicament cartridge retainer for holding a medicament cartridge. A dispense interface can be attached to an attachment of the device for facilitating fluidic communication from the device. Further, an interface sensor is configured to provide an output indicative of whether the dispense interface is attached to the attachment. The device also comprises a piston rod for driving a bung of the medicament cartridge, and a drive train for advancing the piston rod to the bung. A controller is configured to control the drive train to advance the piston rod towards the bung when the output of the interface sensor indicates that the dispense interface is not on the attachment. The controller is further configured to disable advancement of the piston rod when the output of the interface sensor indicates that the dispense interface is at least partially on the attachment.

The invention discloses a suspension seed coating agent prepared with a dinotefuran and difenoconazole compound as active ingredients and with addition of other auxiliary materials. The preparation has the characteristics of high suspension rate, good film-forming performance, uniform seed coatings, high efficiency and low toxicity and the like. While in use, the suspension seed coating agent has good utilization rate, can reduce the amount of drug agents, and effectively reduces environmental pollutions. Compared with a dinotefuran single agent and a difenoconazole single agent, the suspension seed coating agent allows prevention and curing effects of diseases and pests to be significantly improved and has compatible curing effect, and besides, has the effect of promoting seed germination. The suspension seed coating agent is applicable to treatment of seeds of rice, wheat, corn, soybean, peanut and other crops, can be not only mechanically operated but also artificially dressed the seeds during seed treatment, and can meet the needs of different production levels.

Discovered is a blood vessel scaffold with functional nano drug-loaded coating, pertaining to medical apparatus technique field, comprising a tubular network scaffold and drug coating, characterized in that drugs are coated on the tubular network scaffold via functional drug-loaded nano particles. Said drug coating has a percentage composition by wt of: 58.52%-73.67% of functional drug-loaded nano paticles, 15.79%-26.82% of drug agent, and 10.54%-14.66% of additive. The disclosed scaffold can control drug release speed well, realize drug multidimensional release, so that can decrease restenosis occurrence ratio effectively after interventional treatment of blood vessel obstruction patients, decrease complications, and improve survival rate and life quality.

A medicament delivery device is presented for the administration of one or more drug agents, wherein the device comprises a retainer for holding a medicament cartridge. The retainer is moveable between an open and closed position. A position sensor for generating a position output is indicative of whether the retainer is in the open or closed position. Further, a cartridge sensor generates a cartridge output indicative of whether the retainer is holding a medicament cartridge. A controller controls a predetermined operation of the device in dependence on the output of the position sensor and on the output of the cartridge sensor.

A new immunosuppressive agent as glycyrol has significant immunosuppressive activity, thus is useful as an immunosuppressive agent to treat relative diseases, wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza, which is a small molecular compound with novel chemical structure. Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction (MLR), release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection. The glycyrol is a high-effective low-toxicity immunosuppressive agent, with small molecular weight and simple structure, which is easy to be modified and to prepare different drug agents, therefore, the compound is a new generation immunosuppressive agent.

The invention discloses a gastrodine nasal administer drug agent to treat nervous prostration and vascular dementia, which is characterized by the following: adopting gastrodine as main raw material and certain effective drug as auxiliary material; resisting pain; modifying local brain blood flow; targeting brain through gastrodine.

The invention relates to a novel skin regeneration material and a preparation method thereof, and belongs to the biomedical material processing technical field. The skin regeneration material is divided into a drug agent layer and a gel layer, wherein the gel layer is composed of alginate, chitosan, a grease microcapsule powder, nano silver and deionized water. The preparation method comprises the steps of adopting a solution spinning method to obtain an alginate fiber, then pressing with a cladding material and a drug agent to obtain the novel skin regeneration material. The skin regeneration material is capable of protecting wound surfaces, relieving pain, stopping bleeding, diminishing inflammation, promoting growth of newly-born granulation tissues and epithelial cells, accelerating wound surface healing and the like, has the advantages of excellent antibacterial performance, good biological safety and the like, and is wide in application range and suitable for various wound surfaces with a large amount of exudates, various bleeding wounds and various chronic, infected and difficult-to-heal wound surfaces.

The invention discloses a long-effective implantation agent of thymic pentapeptide in the drug agent domain, which is characterized by the following: adopting thymic pentapeptide as treating active material and biologically decomposed material as base; making the appearance as fine rob shape or cylinder shape; injecting or surgerying to transplant into body; releasing drug completely without surgery and fetching; obtaining high-packing rate and drug-carrying quantity to approach constant speed to release one to several months; reducing the medical cost; improving the compliance for patients. The invention has simple preparing technique and high safety, which projects he clinical treatment superiority and good applying prospect.